{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:24:55Z","timestamp":1780417495023,"version":"3.54.1"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>Clinical use of onabotulinumtoxinA evolved based on strategic, hypothesis-driven applications, as well as serendipitous observations by physicians and patients. The success of onabotulinumtoxinA in blepharospasm and strabismus led to its study in other head and neck dystonias, followed by limb dystonia, tremor, and spasticity. The aesthetic use of onabotulinumtoxinA followed initial reports from patients of improved facial lines after injections for facial dystonias and hemifacial spasm. Although patients with dystonias and spasticity regularly reported that their local pain improved after injections, onabotulinumtoxinA was not systematically explored for chronic migraine until patients began reporting headache improvements following aesthetic injections. Clinicians began assessing onabotulinumtoxinA for facial sweating and hyperhidrosis based on its inhibition of acetylcholine from sympathetic cholinergic nerves. Yet another line of research grew out of injections for laryngeal dystonia, whereby clinicians began to explore other sphincters in the gastrointestinal tract and eventually to treatment of pelvic sphincters; many of these sphincters are innervated by autonomic nerves. Additional investigations in other autonomically mediated conditions were conducted, including overactive bladder and neurogenic detrusor overactivity, achalasia, obesity, and postoperative atrial fibrillation. The study of onabotulinumtoxinA for depression also grew out of the cosmetic experience and the observation that relaxing facial muscle contractions associated with negative emotions may improve mood. For approved indications, the safety profile of onabotulinumtoxinA has been demonstrated in the formal development programs and post-marketing reports. Over time, evidence has accumulated suggesting clinical manifestations of systemic effects, albeit uncommon, particularly with high doses and in vulnerable populations. Although onabotulinumtoxinA is approved for approximately 26 indications across multiple local regions, there are 15 primary indication uses that have been approved in most regions, including the United States, Europe, South America, and Asia. This review describes many uses for which AbbVie has not sought and\/or received regulatory approval and are mentioned for historical context only.<\/jats:p>","DOI":"10.1097\/md.0000000000032373","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:00:58Z","timestamp":1690484458000},"page":"e32373","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["The pluripotential evolution and journey of Botox (onabotulinumtoxinA)"],"prefix":"10.1097","volume":"102","author":[{"given":"Mitchell F.","family":"Brin","sequence":"first","affiliation":[{"name":"Allergan\/AbbVie, Irvine, CA, USA"},{"name":"University of California, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blitzer","sequence":"additional","affiliation":[{"name":"Professor Emeritus of Otolaryngology\/Head and Neck Surgery, Columbia University College of Physicians and Surgeons, New York, NY, USA"},{"name":"Adjunct Professor of Neurology, Icahn School of Medicine at Mt. Sinai, New York, NY, USA"},{"name":"Director, NY Center for Voice and Swallowing Disorders, New York, NY, USA"},{"name":"Co-founder and Director of Research, ADN International, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R4-20240803","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032371","article-title":"Early development history of Botox (onabotulinumtoxinA).","author":"Scott","year":"2023","journal-title":"Medicine"},{"key":"R5-20240803","first-page":"1300","article-title":"Botulinum toxin (BOTOX) for the treatment of \u201cspastic dysphonia\u201d as part of a trial of toxin injections for the treatment of other cranial dystonias.","volume":"96","author":"Blitzer","year":"1986","journal-title":"Laryngoscope"},{"key":"R6-20240803","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870020402","article-title":"Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.","volume":"2","author":"Brin","year":"1987","journal-title":"Mov Disord"},{"key":"R7-20240803","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archotol.1987.01860060029009","article-title":"Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report.","volume":"113","author":"Miller","year":"1987","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study.","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"key":"R9-20240803","first-page":"173","article-title":"Interventional neurology: treatment of neurological conditions with local injection of botulinum toxin.","volume":"54","author":"Brin","year":"1991","journal-title":"Arch Neurobiol (Madr)"},{"issue":"6 Pt 1","key":"R10-20240803","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/000348948509400614","article-title":"Electromyographic findings in focal laryngeal dystonia (spastic dysphonia).","volume":"94","author":"Blitzer","year":"1985","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"R11-20240803","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","article-title":"Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients.","volume":"139","author":"Dykstra","year":"1988","journal-title":"J Urol"},{"key":"R12-20240803","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0140-6736(88)90188-2","article-title":"Treatment of anismus in intractable constipation with botulinum A toxin.","volume":"2","author":"Hallan","year":"1988","journal-title":"Lancet"},{"key":"R13-20240803","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(94)90633-5","article-title":"Botulinum toxin for chronic anal fissure.","volume":"344","author":"Gui","year":"1994","journal-title":"Lancet"},{"key":"R14-20240803","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032377","article-title":"Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): development, insights, and impact.","author":"Nitti","year":"2023","journal-title":"Medicine"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0140-6736(05)64862-3","article-title":"Treatment of vaginismus with botulinum toxin injections.","volume":"349","author":"Brin","year":"1997","journal-title":"Lancet"},{"key":"R16-20240803","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032374","article-title":"Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): development, insights, and impact.","author":"Scott","year":"2023","journal-title":"Medicine"},{"key":"R18-20240803","article-title":"Treatment of crow\u2019s feet lines and forehead lines with Botox (onabotulinumtoxinA): development, insights, and impact.","author":"Carruthers","year":"2023","journal-title":"Medicine"},{"key":"R20-20240803","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/archneur.1991.00530240100030","article-title":"National institutes of health consensus development conference statement, November 12-14, 1990.","volume":"48","year":"1991","journal-title":"Arch Neurol"},{"key":"R21-20240803","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00006534-199407000-00009","article-title":"Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study.","volume":"94","author":"Keen","year":"1994","journal-title":"Plast Reconstr Surg"},{"key":"R22-20240803","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archoto.123.4.389","article-title":"The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients.","volume":"123","author":"Blitzer","year":"1997","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R23-20240803","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/000348948909800202","article-title":"Botulinum toxin injection for the treatment of oromandibular dystonia.","volume":"98","author":"Blitzer","year":"1989","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"R24-20240803","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00006534-198908000-00027","article-title":"Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis.","volume":"84","author":"Clark","year":"1989","journal-title":"Plast Reconstr Surg"},{"key":"R25-20240803","doi-asserted-by":"crossref","first-page":"221","DOI":"10.18869\/acadpub.beat.5.4.499","article-title":"Le Fort fractures: a collective review.","volume":"5","author":"Phillips","year":"2017","journal-title":"Bull Emerg Trauma"},{"key":"R26-20240803","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1067\/mhn.2000.110960","article-title":"Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.","volume":"123","author":"Binder","year":"2000","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R27-20240803","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","article-title":"Subcutaneous administration of botulinum toxin A reduces formalin-induced pain.","volume":"107","author":"Cui","year":"2004","journal-title":"Pain"},{"issue":"suppl 1","key":"R28-20240803","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","article-title":"Evidence for antinociceptive activity of botulinum toxin type A in pain management.","volume":"43","author":"Aoki","year":"2003","journal-title":"Headache"},{"key":"R29-20240803","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032600","article-title":"Treatment of chronic migraine with Botox (onabotulinumtoxinA): development, insights, and impact.","author":"Turkel","year":"2023","journal-title":"Medicine"},{"issue":"Pt 16","key":"R30-20240803","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1242\/jcs.012211","article-title":"Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential.","volume":"120","author":"Meng","year":"2007","journal-title":"J Cell Sci"},{"key":"R31-20240803","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102414527648","article-title":"Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains.","volume":"34","author":"Burstein","year":"2014","journal-title":"Cephalalgia"},{"key":"R32-20240803","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0333102416636843","article-title":"Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors\u2019 responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle?","volume":"36","author":"Zhang","year":"2016","journal-title":"Cephalalgia"},{"key":"R33-20240803","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.4081\/ni.2014.5133","article-title":"Botulinum toxin type a for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial.","volume":"6","author":"Hollanda","year":"2014","journal-title":"Neurol Int"},{"issue":"Pt 2","key":"R34-20240803","first-page":"231","article-title":"Free nerve endings in skeletal muscle of the cat.","volume":"105","author":"Stacey","year":"1969","journal-title":"J Anat"},{"key":"R36-20240803","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpainsymman.2016.01.007","article-title":"OnabotulinumtoxinA improves pain in patients with post-stroke spasticity: findings from a randomized, double-blind, placebo-controlled trial.","volume":"52","author":"Wissel","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"R37-20240803","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032372","article-title":"Botox (onabotulinumtoxinA) mechanism of action.","author":"Brin","year":"2023","journal-title":"Medicine"},{"key":"R38-20240803","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032600","article-title":"Treatment of chronic migraine with Botox (onabotulinumtoxinA): development, insights, and impact.","author":"Turkel","year":"2023","journal-title":"Medicine"},{"key":"R39-20240803","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/jnnp.57.11.1437","article-title":"Botulinum toxin and sweating.","volume":"57","author":"Bushara","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R40-20240803","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1113\/jphysiol.1951.sp004551","article-title":"A further survey of the action of Clostridium botulinum toxin upon different types of autonomic nerve fibre.","volume":"113","author":"Ambache","year":"1951","journal-title":"J Physiol"},{"key":"R41-20240803","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032764","article-title":"Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): development, insights, and impact.","author":"Lowe","year":"2023","journal-title":"Medicine"},{"key":"R42-20240803","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.37.5.711","article-title":"Botulism. Studies on the manner in which the toxin of clostridium botulinum acts upon the body: I. The effect upon the autonomic nervous system.","volume":"37","author":"Dickson","year":"1923","journal-title":"J Exp Med"},{"key":"R43-20240803","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0306-9877(97)90103-1","article-title":"Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment--botulinum toxin A injections of the parotid glands.","volume":"48","author":"Bushara","year":"1997","journal-title":"Med Hypotheses"},{"key":"R44-20240803","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jnnp.67.5.697","article-title":"Botulinum toxin is a useful treatment in excessive drooling in saliva.","volume":"67","author":"Bhatia","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R45-20240803","first-page":"65","article-title":"Vasomotor rhinitis.","volume":"19","author":"Kimmelman","year":"1986","journal-title":"Otolaryngol Clin North Am"},{"key":"R46-20240803","first-page":"566","article-title":"Rhinorrhea is decreased in dogs after nasal application of botulinum toxin.","volume":"112","author":"Shaari","year":"1995","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R47-20240803","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1017\/S0022215100158281","article-title":"The effect of botulinum toxin type A injection for intrinsic rhinitis.","volume":"112","author":"Kim","year":"1998","journal-title":"J Laryngol Otol"},{"key":"R48-20240803","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jnnp.52.3.355","article-title":"Treatment of focal dystonias of the hand with botulinum toxin injections.","volume":"52","author":"Cohen","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R49-20240803","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.410280407","article-title":"Treatment of spasticity with botulinum toxin: a double-blind study.","volume":"28","author":"Snow","year":"1990","journal-title":"Ann Neurol"},{"key":"R50-20240803","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/01241398-199307000-00013","article-title":"Management of cerebral palsy with botulinum-A toxin: preliminary investigation.","volume":"13","author":"Koman","year":"1993","journal-title":"J Pediatr Orthop"},{"key":"R51-20240803","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1469-8749.1994.tb11864.x","article-title":"Botulinum toxin in the management of the lower limb in cerebral palsy.","volume":"36","author":"Cosgrove","year":"1994","journal-title":"Dev Med Child Neurol"},{"key":"R52-20240803","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/WNL.41.8.1185","article-title":"Botulinum toxin treatment of tremors.","volume":"41","author":"Jankovic","year":"1991","journal-title":"Neurology"},{"key":"R53-20240803","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.toxicon.2018.01.017","article-title":"Botulinum toxin treatment of pain syndromes\u2014an evidence based review.","volume":"147","author":"Safarpour","year":"2018","journal-title":"Toxicon"},{"key":"R54-20240803","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2147\/JPR.S159700","article-title":"Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature.","volume":"11","author":"Cinone","year":"2018","journal-title":"J Pain Res"},{"key":"R55-20240803","first-page":"529","article-title":"[Botulinum toxin type A treatment of cosmetically disturbing masseteric hypertrophy].","volume":"142","author":"Rijsdijk","year":"1998","journal-title":"Ned Tijdschr Geneeskd"},{"key":"R56-20240803","first-page":"477","article-title":"Botulinum toxin type A treatment for contouring of the lower face.","volume":"29","author":"Park","year":"2003","journal-title":"Dermatol Surg"},{"key":"R57-20240803","first-page":"484","article-title":"Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement.","volume":"29","author":"Kim","year":"2003","journal-title":"Dermatol Surg"},{"key":"R58-20240803","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00266-007-0081-8","article-title":"Botulinum toxin a for lower facial contouring: a prospective study.","volume":"31","author":"Yu","year":"2007","journal-title":"Aesthetic Plast Surg"},{"key":"R59-20240803","first-page":"867","article-title":"Botulinum toxin a for aesthetic contouring of enlarged medial gastrocnemius muscle.","volume":"30","author":"Lee","year":"2004","journal-title":"Dermatol Surg"},{"key":"R60-20240803","first-page":"645","article-title":"Treatment of depression with botulinum toxin A: a case series.","volume":"32","author":"Finzi","year":"2006","journal-title":"Dermatol Surg"},{"key":"R62-20240803","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/cercor\/bhn104","article-title":"The link between facial feedback and neural activity within central circuitries of emotion\u2014new insights from botulinum toxin-induced denervation of frown muscles.","volume":"19","author":"Hennenlotter","year":"2009","journal-title":"Cereb Cortex"},{"key":"R63-20240803","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2045-5380-4-11","article-title":"Botulinum toxin-induced facial muscle paralysis affects amygdala responses to the perception of emotional expressions: preliminary findings from an A-B-A design.","volume":"4","author":"Kim","year":"2014","journal-title":"Biol Mood Anxiety Disord"},{"key":"R65-20240803","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpsychires.2012.01.027","article-title":"Facing depression with botulinum toxin: a randomized controlled trial.","volume":"46","author":"Wollmer","year":"2012","journal-title":"J Psychiatr Res"},{"key":"R66-20240803","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4088\/JCP.13m08845","article-title":"Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.","volume":"75","author":"Magid","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"R67-20240803","first-page":"982","article-title":"Efficacy of Botox versus placebo for treatment of patients with major depression.","volume":"46","author":"Zamanian","year":"2017","journal-title":"Iran J Public Health"},{"key":"R68-20240803","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/YIC.0000000000000290","article-title":"OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females.","volume":"35","author":"Brin","year":"2020","journal-title":"Int Clin Psychopharmacol"},{"key":"R69-20240803","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1523\/JNEUROSCI.3948-05.2006","article-title":"Enhanced long-term potentiation-like plasticity of the trigeminal blink reflex circuit in blepharospasm.","volume":"26","author":"Quartarone","year":"2006","journal-title":"J Neurosci"},{"key":"R70-20240803","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.410290407","article-title":"Change in pattern of muscle activity following botulinum toxin injections for torticollis.","volume":"29","author":"Gelb","year":"1991","journal-title":"Ann Neurol"},{"key":"R71-20240803","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.410320323","article-title":"Modification of muscle activity after BOTOX injections in spasmodic torticollis.","volume":"32","author":"Marin","year":"1992","journal-title":"Ann Neurol"},{"key":"R72-20240803","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1044\/1092-4388(2006\/081)","article-title":"Alterations in CNS activity induced by botulinum toxin treatment in spasmodic dysphonia: an H215O PET study.","volume":"49","author":"Ali","year":"2006","journal-title":"J Speech Lang Hear Res"},{"issue":"Pt 1","key":"R73-20240803","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/brain\/awh665","article-title":"Silent event-related fMRI reveals deficient motor and enhanced somatosensory activation in orofacial dystonia.","volume":"129","author":"Dresel","year":"2006","journal-title":"Brain"},{"key":"R74-20240803","doi-asserted-by":"crossref","first-page":"e0168652","DOI":"10.1371\/journal.pone.0168652","article-title":"Grey matter microstructural integrity alterations in blepharospasm are partially reversed by botulinum neurotoxin therapy.","volume":"11","author":"Alexandru","year":"2016","journal-title":"PLoS One"},{"key":"R75-20240803","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4070\/kcj.2010.40.8.387","article-title":"Short-term autonomic denervation of the atria using botulinum toxin.","volume":"40","author":"Oh","year":"2010","journal-title":"Korean Circ J"},{"key":"R76-20240803","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/CIRCEP.111.961854","article-title":"Botulinum toxin injection in epicardial autonomic ganglia temporarily suppresses vagally mediated atrial fibrillation.","volume":"4","author":"Oh","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R77-20240803","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.hrthm.2018.08.021","article-title":"Temporary autonomic modulation with botulinum toxin type A to reduce atrial fibrillation after cardiac surgery.","volume":"16","author":"Waldron","year":"2019","journal-title":"Heart Rhythm"},{"key":"R78-20240803","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ahj.2021.10.114","article-title":"Design and rationale of a Phase 2 study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation \u2013 The NOVA Study.","volume":"245","author":"Piccini","year":"2022","journal-title":"Am Heart J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:56:23Z","timestamp":1722736583000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":70,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032373","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}